Mechanisms of Hepatocyte Zonation Disruption in Liver Disease

Abstract

Hepatocyte zonation, the spatial segregation of metabolic activities within the liver lobule, is central to hepatic physiology and homeostasis. In liver disease, this zonation is disrupted, profoundly impacting liver function and disease progression. This review examines the mechanisms underlying hepatocyte zonation disruption in liver disease, integrating recent experimental and clinical data to elucidate pathophysiological processes, risk factors, clinical implications, and emerging therapeutic approaches. Emphasis is placed on molecular signaling pathways, microenvironmental changes, and clinical relevance for hepatologists and healthcare professionals managing liver pathology.

Introduction

The liver’s unique organization into metabolic zones—periportal (zone 1), midzonal (zone 2), and pericentral (zone 3)—enables efficient substrate processing, detoxification, and synthetic functions. Hepatocyte zonation is orchestrated by intricate gradients of oxygen, nutrients, hormones, and signaling molecules. Disruption of this zonation is increasingly recognized as a key feature and driver of various liver diseases, including nonalcoholic steatohepatitis (NASH), viral hepatitis, alcoholic liver disease (ALD), and cirrhosis. Understanding the mechanisms of zonation disruption provides insights into disease pathogenesis, diagnostic markers, and targeted therapies.

Epidemiology / Disease Burden

Liver diseases resulting in disruption of hepatocyte zonation are globally prevalent. Nonalcoholic fatty liver disease (NAFLD) affects over 25% of the world’s population, while chronic hepatitis B and C, and ALD, remain major causes of morbidity and mortality. The global burden of cirrhosis and hepatocellular carcinoma, sequelae of chronic liver injury and zonation loss, continues to rise. Epidemiological studies highlight that zonation disruption correlates with disease progression, poor prognosis, and increased risk of liver-related complications, emphasizing the need for early detection and intervention.

Pathophysiology

Hepatocyte zonation is maintained by the interplay of morphogen gradients (notably Wnt/β-catenin, Hedgehog, and Hippo pathways), oxygen tension, and extracellular matrix components. In liver disease, chronic injury induces hypoxia, inflammation, and fibrogenesis, which disturb these gradients. For instance, pericentral hypoxia upregulates hypoxia-inducible factors (HIFs), altering metabolic gene expression and promoting dedifferentiation of hepatocytes. Inflammatory cytokines (e.g., TNF-α, IL-6) and oxidative stress further disrupt signaling networks, leading to loss of distinct zonal patterns. Fibrosis and vascular remodeling blunt the sinusoidal flow, exacerbating zonation loss. Recent single-cell transcriptomic analyses have mapped these changes, revealing loss of pericentral and periportal signatures in advanced disease.

Risk Factors

Risk factors for hepatocyte zonation disruption mirror those for chronic liver disease: obesity, metabolic syndrome, excessive alcohol intake, chronic viral hepatitis, genetic predisposition (e.g., PNPLA3 polymorphisms), and environmental toxins. These factors promote sustained liver injury, inflammation, and fibrogenesis, directly perturbing zonation-maintaining pathways. For example, insulin resistance and hyperglycemia alter periportal gluconeogenic activity, while alcohol and toxins preferentially damage pericentral hepatocytes. Cumulative exposure and synergistic risk factors accelerate zonation loss and liver dysfunction.

Clinical Features

Clinically, disruption of hepatocyte zonation manifests as derangements in metabolic, synthetic, and detoxification functions. Early features may be subtle—mild elevations in aminotransferases, dysregulated lipid and glucose metabolism, or altered drug clearance. As zonation loss progresses, patients may develop features of hepatic insufficiency: jaundice, coagulopathy, hypoalbuminemia, and hepatic encephalopathy. Histologically, loss of the normal lobular architecture, ballooning degeneration, and bridging fibrosis are hallmarks. The severity of zonation disruption often parallels disease progression and clinical decompensation.

Diagnosis

Diagnosis of zonation disruption remains indirect, relying on clinical, laboratory, imaging, and histological assessment. Liver biopsy, while invasive, allows visualization of lobular architecture and zonal injury patterns. Immunohistochemistry for zone-specific markers (e.g., glutamine synthetase for zone 3, carbamoyl phosphate synthetase for zone 1) can reveal loss of zonal identity. Noninvasive imaging techniques, such as multiparametric MRI and elastography, provide adjunctive information on liver structure and function. Emerging omics approaches, including spatial transcriptomics, hold promise for noninvasively mapping zonation loss in vivo.

Treatment & Management

Management strategies target underlying liver disease to mitigate further zonation disruption. Lifestyle modification, pharmacotherapy (e.g., antivirals for hepatitis, insulin sensitizers for NAFLD), and alcohol cessation are fundamental. Antifibrotic agents and antioxidants are under investigation, aiming to restore zonal signaling and prevent architectural derangement. In advanced cases, liver transplantation remains the definitive therapy. Supportive management of complications (ascites, encephalopathy) is essential in decompensated disease.

Recent Advances / Emerging Therapies

Recent advances have illuminated the regenerative potential of hepatocyte zonation. Modulation of Wnt/β-catenin signaling, use of small molecules to enhance pericentral or periportal functions, and stem cell therapies are actively explored. Preclinical models suggest that restoration of zonal gene expression can improve metabolic and synthetic capacity. Gene editing and organoid technologies may allow future personalized interventions. Clinical trials investigating FXR agonists, GLP-1 analogs, and antifibrotic agents are ongoing, some showing promise for reversing or stabilizing zonation loss.

Guideline Recommendations

Current guidelines from AASLD, EASL, and other hepatology societies emphasize early identification and treatment of chronic liver diseases to prevent progression and zonation disruption. Regular monitoring, risk factor modification, and tailored pharmacotherapy are recommended. While direct therapies targeting zonation are not yet standard, ongoing research is expected to inform future guidelines.

Conclusion

Disruption of hepatocyte zonation is a critical pathophysiological feature of liver disease, contributing to metabolic dysfunction, disease progression, and poor outcomes. Understanding the molecular mechanisms underlying zonation loss provides a foundation for novel diagnostic, prognostic, and therapeutic strategies. Ongoing research into signaling pathways, microenvironmental changes, and regenerative therapies holds promise for restoring hepatic architecture and function, improving patient outcomes in chronic liver disease.